News and Events
The results of Phase 2 clinical trials for glaucoma drug QLS-101 have demonstrated a favorable safety and tolerability profile, according to a news release by Qlaris Bio, which licensed the drug in 2019. A positive efficacy signal was also reported.
The Midwest Antiviral Drug Discovery (AViDD) Center is part of a network of nine national centers established in response to the public health emergency.
This spring phase I/II clinical trials began for QLS-101: a novel prodrug developed by the ITDD's Dr. Peter Dosa in collaboration with Dr. Michael Fautsch of the Mayo Clinic. The licensee for the drug, Qlaris Bio, has now created a video to explain how the drug reduces the pressure inside the eye, with the hopes of providing relief to people with increased eye pressure. You can watch the video here.
Congratulations to Dr. Elizabeth Ambrose for her appointment to the editorial board for the journal of Bioorganic Chemistry!
Graduate student Alex Hurben of the Tretyakova lab has been awarded the Exceptional Presentation Award in Chemical Biology at the American Chemical Society's 2021 Great Lakes Regional Meeting. His presentation "Shining a Light on Endogenous Electrophiles: Releasing Methylglyoxal with Spatiotemporal Control in Biological Systems" took place at the Chemical Biology Interface session on June 9th.
Congratulations to our graduate students who have been awarded 2021 fellowships from the University of Minnesota's College of Pharmacy!
Thanks to a research collaboration between the Institute for Therapeutics Discovery & Develoment and Mayo Clinic, a drug that shows promise for glaucoma patients has moved to Phase I/II clinical trials.
Congratulations to Connor McDermott who was selected to receive a 2020-2021 Outstanding TA Award by the University of Minnesota's College of Pharmacy! This marks the second year in a row that he has been selected for the award. Connor is a graduate student in Dr.
Congratulations to Dr. Dan Harki for his promotion to Full Professor! Dr. Harki has been with the Department of Medicinal Chemistry since 2009 and also serves as the Director of Graduate Studies and as Co-Leader for the Cellular Mechanisms Program in the Masonic Cancer Center.
Work in Dr. Elizabeth Ambrose's lab has been featured in recent publications by both Genetic Engineering & Biotechnology News and in the German publication Focus Online.